基于人工智能的[18F]FDG PET/CT骨髓代谢活性体积评估预测多发性骨髓瘤生存
本研究纳入44例初治多发性骨髓瘤患者,采用人工智能工具在[18F]FDG PET/CT上自动分割骨髓并计算全身代谢肿瘤体积(MTV)和病灶糖酵解总量(TLG),应用10种基于参考器官或绝对SUV值的摄取阈值。中位随访110个月,结果显示MTV和TLG与骨髓浆细胞浸润程度相关,以肝脏摄取为参考的MTV可预测无进展生存和总生存。
要点
- 基于人工智能的全身骨髓MTV和TLG计算在全部44例初治多发性骨髓瘤患者中可行。
- 10种[18F]FDG摄取阈值下,MTV和TLG均与骨髓浆细胞浸润呈显著正相关。
- 以肝脏摄取为参考的MTV在多变量分析中与更短的总生存显著相关。
核心结论
- 基于人工智能的全身骨髓代谢参数MTV和TLG不仅与骨髓浆细胞浸润程度相关,还能预测多发性骨髓瘤患者生存。
- 以肝脏摄取为参考进行骨髓分割的MTV为疾病进展提供了可靠的预后信息。
研究设计与样本
- 研究纳入44例既往未治疗的多发性骨髓瘤患者,行全身[18F]FDG PET/CT检查。
- 基于CT的骨骼初始分割转移至SUV PET图像,应用不同SUV阈值并通过后处理优化区域,实现自动图像分割和骨髓代谢体积定量。
- 应用10种基于参考器官或绝对SUV值的摄取阈值(人工智能方法)定义病理性示踪剂摄取,计算全身MTV和TLG。
- 分析自动PET值与骨髓组织病理学结果、无进展生存和总生存的相关性,并用ROC曲线分析MTV和TLG对2年无进展生存的预测效能。
- 同时评估意大利多发性骨髓瘤PET应用新标准(IMPeTUs)的预后效能。
主要发现
- 患者队列中位随访[95%CI]为110个月[105-123个月]。
- 人工智能骨髓分割及MTV、TLG计算在全部患者中可行。
- 全部10种[18F]FDG摄取阈值下,自动定量全身PET/CT参数MTV和TLG与骨髓浆细胞浸润呈显著正相关,相关性中等。
- 无进展生存方面,单变量分析显示所有人工智能方法的MTV和TLG均能较好地预测患者结局。
- 调整细胞遗传学异常和骨髓浆细胞浸润率后,多变量分析显示高MTV(以肝脏为参考定义骨髓病理性[18F]FDG摄取)仍具有预后意义。
关键数值与推荐
- 应用10种基于参考器官或绝对SUV值的摄取阈值(人工智能方法)定义病理性示踪剂摄取并计算全身MTV和TLG。
- 以肝脏摄取为参考进行骨髓分割的MTV在多变量分析中显示预后意义。
- IMPeTUs评估中,局灶性高代谢骨髓病灶数目和髓外疾病对无进展生存有不良影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multiple myeloma (MM) is a highly heterogeneous disease with wide variations in patient outcome. [18F]FDG PET/CT can provide prognostic information in MM, but it is hampered by issues regarding standardization of scan interpretation. Our group has recently demonstrated the feasibility of automated, volumetric assessment of bone marrow (BM) metabolic activity on PET/CT using a novel artificial intelligence (AI)-based tool. Accordingly, the aim of the current study is to investigate the prognostic role of whole-body calculations of BM metabolism in patients with newly diagnosed MM using this AI tool. MATERIALS AND METHODS: Forty-four, previously untreated MM patients underwent whole-body [18F]FDG PET/CT. Automated PET/CT image segmentation and volumetric quantification of BM metabolism were based on an initial CT-based segmentation of the skeleton, its transfer to the standardized uptake value (SUV) PET images, subsequent application of different SUV thresholds, and refinement of the resulting regions using postprocessing. In the present analysis, ten different uptake thresholds (AI approaches), based on reference organs or absolute SUV values, were applied for definition of pathological tracer uptake and subsequent calculation of the whole-body metabolic tumor volume (MTV) and total lesion glycolysis (TLG). Correlation analysis was performed between the automated PET values and histopathological results of the BM as well as patients' progression-free survival (PFS) and overall survival (OS). Receiver operating characteristic (ROC) curve analysis was used to investigate the discrimination performance of MTV and TLG for prediction of 2-year PFS. The prognostic performance of the new Italian Myeloma criteria for PET Use (IMPeTUs) was also investigated. RESULTS: Median follow-up [95% CI] of the patient cohort was 110 months [105-123 months]. AI-based BM segmentation and calculation of MTV and TLG were feasible in all patients. A significant, positive, moderate correlation was observed between the automated quantitative whole-body PET/CT parameters, MTV and TLG, and BM plasma cell infiltration for all ten [18F]FDG uptake thresholds. With regard to PFS, univariable analysis for both MTV and TLG predicted patient outcome reasonably well for all AI approaches. Adjusting for cytogenetic abnormalities and BM plasma cell infiltration rate, multivariable analysis also showed prognostic significance for high MTV, which defined pathological [18F]FDG uptake in the BM via the liver. In terms of OS, univariable and multivariable analysis showed that whole-body MTV, again mainly using liver uptake as reference, was significantly associated with shorter survival. In line with these findings, ROC curve analysis showed that MTV and TLG, assessed using liver-based cut-offs, could predict 2-year PFS rates. The application of IMPeTUs showed that the number of focal hypermetabolic BM lesions and extramedullary disease had an adverse effect on PFS. CONCLUSIONS: The AI-based, whole-body calculations of BM metabolism via the parameters MTV and TLG not only correlate with the degree of BM plasma cell infiltration, but also predict patient survival in MM. In particular, the parameter MTV, using the liver uptake as reference for BM segmentation, provides solid prognostic information for disease progression. In addition to highlighting the prognostic significance of automated, global volumetric estimation of metabolic tumor burden, these data open up new perspectives towards solving the complex problem of interpreting PET scans in MM with a simple, fast, and robust method that is not affected by operator-dependent interventions.
引用
- Sachpekidis C, Enqvist O, Ulén J, et al. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2024. PMID: 38456971. doi:10.1007/s00259-024-06668-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。